Given the quarterly hints, I have a few questions, and I would love others' opinions. 1. They mention local and global partners. Would I be right in saying that these could be two separate sources of investment? The local partners get the Australian market. Global partner (I'll assume it is US from the location of the presentation) gets the USA. If they could get two licensing deals with upfront payments, that could solve many issues. 2. when is early 2025? If discussions are expected to conclude in Early 2025, by my definition, that is the first quarter. By the end of March, maybe April at the latest. Then it becomes Mid 2025. 3. Is this activity the result of the new director? Could be a great appointment. 4. If there is a deal, I believe it signals that Paul has some indication of the early results. A deal is not just a positive in terms of money but I believe it is the double whammy of positive results. Paul would have had to have figures to "sell" to the investors. 5. is the continually advancing licensing agreement for cbd capsules separate to the clinical trial and if so isn't it about time to say yes to someone.
AVE Price at posting:
0.4¢ Sentiment: Buy Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)